Victoza Injection
NDC Package 0169-4060-98
Package Information
Victoza (liraglutide) injection is a medication used with a doctor-approved exercise, behavior change, and reduced-calorie diet program to help you lose weight. This formulation utilizes a injection delivery system. Marketed by Novo Nordisk, this product is identified by NDC 0169-4060 and is authorized under FDA application NDA022341.
Identification & Billing
- RxCUI: 897122 - liraglutide 6 MG/ML in 3 ML Pen Injector
- RxCUI: 897122 - 3 ML liraglutide 6 MG/ML Pen Injector
- RxCUI: 897122 - liraglutide 18 MG per 3 ML Pen Injector
- RxCUI: 897126 - Victoza 6 MG/ML in 3 ML Pen Injector
- RxCUI: 897126 - 3 ML liraglutide 6 MG/ML Pen Injector [Victoza]
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 0169 - Novo Nordisk
- 0169-4060 - Victoza
- 0169-4060-98 - 1 SYRINGE, PLASTIC in 1 CARTON / 3 mL in 1 SYRINGE, PLASTIC
- 0169-4060 - Victoza
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (0169-4060). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 0169-4060-98 identifies a specific commercial package of 1 syringe, plastic in 1 carton / 3 ml in 1 syringe, plastic of Victoza, a human prescription drug labeled by Novo Nordisk. This injection is formulated for subcutaneous use and contains liraglutide as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Novo Nordisk on January 25, 2010. The current certification is valid through December 31, 2026.
What are the primary indications for this medication?
This medication is used with a doctor-approved exercise, behavior change, and reduced-calorie diet program to help you lose weight. It is used by certain overweight people, such as those who are obese or have weight-related medical problems. Losing weight and keeping it off can lessen the many health risks that come with obesity, including heart disease, diabetes, high blood pressure, and a shorter life. Liraglutide is similar to a natural hormone in your body (incretin). It works by controlling your appetite.
How is this Novo Nordisk product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 00169406098. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Labeler segment to maintain the 5-4-2 structure.
